Cover Image

Long-Term Survival of Cutaneous Malignant Melanoma with Metastasis to Paranasal Sinuses: A Case Report and Literature Review

Kazem Anvari, Mohammad Reza Majidi, Mahdi Razmara Ferezghi, Bahereh Parkam, Seyed Alireza Javadinia

Background: Malignant melanoma (MM) usually present with metastases to unexpected regions of the body. Metastatic MM is a highly lethal condition, and the median survival in this setting is 6 to 7.5 months; however, few reports rarely describe long-term after chemotherapy.Case Report: We describe a 31-year-old man with MM, which got metastatic (to paranasal sinuses) after local and systemic therapy showed complete responses with long-term survival after endonasal endoscopic metastasectomy and radiotherapy of the nasal cavity, paranasal sinuses, and base of the skull.Conclusion: Although long-term survival is rare, few reports describe cases after chemotherapy. MM could be associated with metastasis to any regions and clinicians should be aware of its behavior and perform complete investigation in the presence of any suspicious symptoms, and this should be reinforced periodically. However, the survival is poor in the metastatic setting, and the treatment of choice is debatable, some patients may benefit from metastasectomy and local radiotherapy. [GMJ.2018;7:e860]

Melanoma; Cutaneous Malignant; Paranasal Sinuses; Survival

Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002;29:427-45.


Propper DJ, Braybrooke JP, Levitt NC, O'Byrne K, Christodoulos K, Han C et al. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British Journal of Cancer. 2000;82(11):1759-63.

PMid:10839287 PMCid:PMC2363219

Balch CM, Gershenwald JE, Soong S-j, Thompson JF, Atkins MB, Byrd DR et al. Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology. 2009;27(36):6199-206.

PMid:19917835 PMCid:PMC2793035

Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC, Slominski A. Current concepts of metastasis in melanoma. Expert review of dermatology. 2008;3(5):569-85.

PMid:19649148 PMCid:PMC2601641

Hill GJ, 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984;53(6):1299-305.<1299::AID-CNCR2820530613>3.0.CO;2-4

Berd D, Mastrangelo MJ. Combination chemotherapy of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995;13(3):796-7.


Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 1994;5(3):249-51.

Durando X, Thivat E, D'Incan M, Sinsard A, Madelmont JC, Chollet P. Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives. BMC cancer. 2005;5:147.

PMid:16287507 PMCid:PMC1310625

Samuel LM, Harvey VJ, Mitchell PL, Thompson PI, Mak D, Melville P et al. Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. European journal of cancer (Oxford, England : 1990). 1994;30a(14):2054-6.

Petit T, Borel C, Rixe O, Avril MF, Monnier A, Giroux B et al. Complete remission seven years after treatment for metastatic malignant melanoma. Cancer. 1996;77(5):900-2.<900::AID-CNCR14>3.0.CO;2-7


  • There are currently no refbacks.